Retina | Ophthalmology Innovation Source

PanOptica Offers a “Do it Yourself” Treatment for Neovascular AMD

PanOptica – Paul Chaney, President & CEO for PanOptica, expands upon averting intravitreal injections with a topically, self-administered eye drop to treat Neovascular AMD. Striving to decrease the burden of injections and injection related risks, Paul shares the company’s unique discovery that led to their many successes. Presenter: Paul Chaney Paul G. Chaney is Co-Founder,…

Ophthotech Introduces Their Antigen for WetAMD

David Guyer, CEO, discusses their novel anti-PDGF antigen for Wet AMD. Using FlowVista in combination with standard of care anti-VEGF therapy, David expands on the products successes, which have led to phase three testing and secured financing. Presenter: David Guyer, MD Under Dr. Guyer’s leadership, Ophthotech raised more than $350 million in financing from May…

iCo Therapeutics Sidesteps VEGF in Diabetic Macular Edema

iCo Therapeutics – Andrew Rae, President & CEO for iCo Therapeutics, shares the company’s focus on diabetic macular edema and their 187 patient study, which is fully enrolled in the U.S. Viewing an opportunity to better serve this population, ICO Therapeutics talks about their products that provide improved outcomes for patients not responding or only…

ALG1001 Leads Allegro’s Progress in Retinal Diseases

Vicken Karageozian, Co-Founder & CTO for Allegro Ophthalmics, shares his company’s story and highlights the progress of their lead molecule, ALG1001, a lead program for several retinal diseases. This program offers a long duration of effect, the option of using combination therapy and treatment for patients who have plateaued or are no longer responding to…

NPP Meets the Mark for Kala Pharmaceuticals

[creativ_media type=”vimeo” url=”https://vimeo.com/82003104″] Guillaume Pfefer, President & CEO, shares Kala Pharmaceutical’s breakthrough technology Nucleolus Penetrating Particle with the audience of the 5th Annual Ophthalmology Innovation Summit. Detailing how this technology benefits a variety of conditions, Guillaume explains how the NPP can be leveraged to treat, post cataract surgery inflammation, dry eye, plethoritis and a demonstration…

RXi Shortens Strands for Effective Drug Delivery

Geert Cauwenbergh, President & CEO for RXi Pharmaceuticals, shares the company’s role in making RNAI relevant to ophthalmology. Highlighting their research surrounding the delivery of drug to the eye, Geert expands on their unique modification to create shorter passenger strands to accompany the longer guide strand to facilitate delivery to the eye effectively. Presenter: Geert…

Funding Ophthalmology Innovation: The Focus of Science and Capital

Ophthalmology is a growing, but challenging, market. Innovation is abounding in its research stages and some people in the know foresee more positive development in breakthrough technologies by 2020, while delivering drugs to the back of the eye is up front in the minds and agendas of investors and innovators. Market data and dialogue indicate…

All Eyes on Ophthalmic Innovation: An Interview with Bill Link

The ophthalmology drug, device and medical technology sector is poised for continued growth, as innovators and entrepreneurs unblinkingly stare down the ongoing domino effect being caused by an aging population, which begets a proliferation in eye disease incidence, which, in turn, begets an unprecedented patient base that consequently requires the types of novel ophthalmic products…

2013 OIS Ophthalmology Innovation Award Ceremony

Bill Link, Managing Director for Versant Ventures presents the first ever “Eye on Innovation Award” during the 2nd Annual Ophthalmology Innovation Summit on April 18, 2013. Expressing the importance of SecondSight’s upcoming technology, Bill provides a brief explanation of the company’s achievement before inviting them to accept the award and present on their innovative technology.…